Zhejiang Huahai Pharmaceutical Past Earnings Performance
Past criteria checks 3/6
Zhejiang Huahai Pharmaceutical has been growing earnings at an average annual rate of 11.5%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been growing at an average rate of 11.4% per year. Zhejiang Huahai Pharmaceutical's return on equity is 12.7%, and it has net margins of 12.2%.
Key information
11.5%
Earnings growth rate
10.9%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | 11.4% |
| Return on equity | 12.7% |
| Net Margin | 12.2% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Zhejiang Huahai Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 9,349 | 1,140 | 3,053 | 1,003 |
| 30 Jun 24 | 9,143 | 1,010 | 2,917 | 996 |
| 31 Mar 24 | 8,748 | 928 | 2,757 | 995 |
| 31 Dec 23 | 8,309 | 830 | 2,584 | 983 |
| 30 Sep 23 | 8,635 | 1,095 | 2,582 | 922 |
| 30 Jun 23 | 8,736 | 1,169 | 2,729 | 913 |
| 31 Mar 23 | 8,552 | 1,203 | 2,605 | 910 |
| 31 Dec 22 | 8,266 | 1,168 | 2,579 | 926 |
| 30 Sep 22 | 7,884 | 692 | 2,617 | 1,043 |
| 30 Jun 22 | 7,432 | 540 | 2,553 | 1,023 |
| 31 Mar 22 | 6,919 | 370 | 2,547 | 1,006 |
| 31 Dec 21 | 6,644 | 488 | 2,463 | 942 |
| 30 Sep 21 | 6,212 | 679 | 2,325 | 757 |
| 30 Jun 21 | 6,215 | 867 | 2,153 | 694 |
| 31 Mar 21 | 6,412 | 964 | 2,096 | 603 |
| 31 Dec 20 | 6,485 | 930 | 2,109 | 566 |
| 30 Sep 20 | 6,247 | 898 | 1,969 | 532 |
| 30 Jun 20 | 6,041 | 813 | 2,041 | 503 |
| 31 Mar 20 | 5,760 | 655 | 1,999 | 485 |
| 31 Dec 19 | 5,388 | 570 | 1,846 | 467 |
| 30 Sep 19 | 5,263 | 364 | 2,110 | 429 |
| 30 Jun 19 | 5,209 | 213 | 2,090 | 410 |
| 31 Mar 19 | 5,055 | 81 | 2,170 | 411 |
| 31 Dec 18 | 5,095 | 108 | 2,154 | 397 |
| 30 Sep 18 | 5,335 | 409 | 1,861 | 398 |
| 30 Jun 18 | 5,190 | 573 | 1,548 | 536 |
| 31 Mar 18 | 5,112 | 661 | 1,474 | 437 |
| 31 Dec 17 | 5,002 | 639 | 1,543 | 353 |
| 30 Sep 17 | 4,680 | 601 | 1,624 | 237 |
| 30 Jun 17 | 4,460 | 537 | 1,778 | 0 |
| 31 Mar 17 | 4,254 | 519 | 1,642 | 0 |
| 31 Dec 16 | 4,093 | 501 | 1,495 | 0 |
| 30 Sep 16 | 4,001 | 492 | 1,423 | 0 |
| 30 Jun 16 | 3,848 | 466 | 1,372 | 0 |
| 31 Mar 16 | 3,738 | 464 | 1,259 | 0 |
| 31 Dec 15 | 3,500 | 442 | 1,166 | 0 |
| 30 Sep 15 | 3,201 | 399 | 992 | 0 |
| 30 Jun 15 | 3,071 | 372 | 900 | 0 |
| 31 Mar 15 | 2,793 | 313 | 836 | 0 |
| 31 Dec 14 | 2,585 | 266 | 796 | 0 |
| 30 Sep 14 | 2,406 | 277 | 702 | 0 |
| 30 Jun 14 | 2,220 | 265 | 649 | 0 |
| 31 Mar 14 | 2,224 | 310 | 598 | 0 |
| 31 Dec 13 | 2,296 | 359 | 555 | 0 |
Quality Earnings: 600521 has high quality earnings.
Growing Profit Margin: 600521's current net profit margins (12.2%) are lower than last year (12.7%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 600521's earnings have grown by 11.5% per year over the past 5 years.
Accelerating Growth: 600521's earnings growth over the past year (4.1%) is below its 5-year average (11.5% per year).
Earnings vs Industry: 600521 earnings growth over the past year (4.1%) exceeded the Pharmaceuticals industry -2.5%.
Return on Equity
High ROE: 600521's Return on Equity (12.7%) is considered low.